Your browser doesn't support javascript.
loading
Epidemiology of growth hormone deficiency in children and adolescents: a systematic review.
Mameli, Chiara; Guadagni, Liliana; Orso, Massimiliano; Calcaterra, Valeria; Wasniewska, Malgorzata Gabriela; Aversa, Tommaso; Granato, Simona; Bruschini, Pietro; d'Angela, Daniela; Spandonaro, Federico; Polistena, Barbara; Zuccotti, Gianvincenzo.
Affiliation
  • Mameli C; Department of Pediatrics, Buzzi Children's Hospital, Milan, Italy.
  • Guadagni L; Department of Biomedical and Clinical Science, Università Di Milano, Milan, Italy.
  • Orso M; Department of Surgical and Biomedical Sciences, University of Perugia, Perugia, Italy.
  • Calcaterra V; C.R.E.A. Sanità (Centre for Applied Economic Research in Healthcare), Rome, Italy. m.orso@creasanita.it.
  • Wasniewska MG; Department of Pediatrics, Ospedale dei Bambini V. Buzzi, Milan, Italy.
  • Aversa T; Department of Internal Medicine and Therapeutics Università degli Studi di Pavia, Pavia, Italy.
  • Granato S; Pediatric Unit, AOU Policlinico "G. Martino", Messina, Italy.
  • Bruschini P; Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.
  • d'Angela D; Pediatric Unit, AOU Policlinico "G. Martino", Messina, Italy.
  • Spandonaro F; Department of Human Pathology of Adulthood and Childhood, University of Messina, Messina, Italy.
  • Polistena B; Medical Department, Pfizer Italia, Rome, Italy.
  • Zuccotti G; Medical Department, Pfizer Italia, Rome, Italy.
Endocrine ; 85(1): 91-98, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38498128
ABSTRACT

OBJECTIVE:

Growth hormone deficiency (GHD) is the most common pituitary hormone deficiency and is one of the main causes of short stature in children and adolescents. The aim of this study is to evaluate the epidemiology of pediatric GHD worldwide, since no other systematic review has been published so far.

METHODS:

We searched PubMed, Embase, and Web of Science up to July 2023 to find epidemiological studies involving children with GHD. Two review authors independently screened articles, extracted data and performed the quality assessment.

RESULTS:

We selected 9 epidemiological studies published from 1974 to 2022. The range of prevalence was 1/1107-1/8,646. A study based on a registry of GH users in the Piedmont region (Italy) reported the highest mean prevalence. In the included studies, the mean incidence ranged from 1/28,800 to 1/46,700 cases per year. One study reported a 20-year cumulative incidence of 127/100,000 for boys and 93/100,000 for girls. Studies were heterogeneous in terms of population (age and GHD etiology) and diagnostic criteria. As for the methodological quality of included studies, all but one study satisfied the majority of the checklist items.

CONCLUSIONS:

The included studies are mostly European, so the provided estimates cannot be considered global. International multicentre studies are needed to compare epidemiological estimates of GHD among different ethnical groups. Considering the considerable cost of human recombinant GH, the only available therapy to treat GHD, understanding accurate epidemiological estimates of GHD in each country is fundamental for resource allocation.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Human Growth Hormone Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Endocrine Year: 2024 Document type: Article

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Human Growth Hormone Limits: Adolescent / Child / Female / Humans / Male Language: En Journal: Endocrine Year: 2024 Document type: Article